Affimed Therapeutics AG expands clinical development team
(Thomson Reuters ONE) -
Affimed Therapeutics AG / Affimed Therapeutics AG expands clinical development team processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Heidelberg, March 08 2010: In preparation for the clinical entry of its first
product candidate Affimed Therapeutics AG, the therapeutic TandAb antibody
company with innovative methods of treatment against life-threatening diseases
expands its development team with an experienced expert.
Effective immediately, Dr Christian Hucke takes over responsibility for planning
and implementation of the clinical development programs at Affimed. Dr Hucke
joins Affimed from Grünenthal GmbH.
Christian Hucke has long-term experience in conception and management of
clinical studies. At Grünenthal he had the overall responsibility for a
worldwide Phase-III-Study in pain therapy of cancer patients as well as a
Proof-of-Concept-Phase-II-Study against diabetic polyneuropathy. Previously, Dr
Hucke worked in clinical drug development at PAION Deutschland GmbH and the
ClinPharmCologne TROPON GmbH. In the course of his various activities he was
responsible for more than 12 Phase-I, II- and III-Studies in diverse
indications. Christian Hucke is a doctor in biology with focus on immunology.
After graduating and obtaining a doctorate degree in Düsseldorf he worked at the
institute of Medical Microbiology at the Heinrich-Heine University of
Düsseldorf.
Dr Rolf H. Günther, CEO of Affimed, commented: "The year 2010 will be a very
important and decisive year for Affimed: both our lead-products will enter the
clinic in 2010. In this crucial phase, Christian Hucke will hold a key position
in our development team."
Dr Christian Hucke added: "I am looking forward to this challenging task in an
innovative company. With its unique TandAb platform Affimed set standards for
the development of new antibody therapeutics. It is a special challenge to be
involved in the clinical development from the very beginning."
For further information please contact:
Affimed Therapeutics AG MC Services AG
Dr. Rolf H. Günther (CEO) Birte Stein
Tel.: + 49 6221 65307-0 Tel.: +49 89 210 228 12
Fax: + 49 6221 65307 77 Fax: +49 89 210 228 88
R.Guenther(at)affimed.com Birte.Stein(at)mc-services.eu
About Affimed Therapeutics AG:
Affimed Therapeutics AG is a therapeutic antibody company developing unique
antibody therapeutics as novel treatments for life threatening diseases with
high unmet medical need. The company has been generating a growing pipeline of
anticancer drug candidates based on its proprietary TandAb technology platform.
Affimed's lead product candidate AFM 13 for the treatment of Hodgkin's disease
has successfully completed preclinical development and will enter clinical
studies in early 2010. Both AFM 11 and AFM 12 to treat Non-Hodgkin's lymphoma
are currently in preclinical development and are expected to begin clinical
studies in late 2010. Further novel product candidates are being developed for
the treatment of solid tumors, autoimmune diseases and asthma. Affimed's
proprietary and highly productive TandAb technology enables the company to
generate unique tetravalent, bispecific, fully human antibody formats that
promise increased therapeutic potential and superior profiles compared to
monoclonal antibodies. The private company Affimed, which employs 26 people in
Heidelberg, is a spin-off from the German Cancer Research Centre (DKFZ
[HUG#1391594]
--- End of Message ---
Affimed Therapeutics AG
Im Neuenheimer Feld 582 Heidelberg Germany
Press release (PDF): http://hugin.info/142251/R/1391594/349421.pdf
Unternehmensinformation / Kurzprofil:
Datum: 08.03.2010 - 10:30 Uhr
Sprache: Deutsch
News-ID 14559
Anzahl Zeichen: 0
contact information:
Town:
Heidelberg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 250 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Affimed Therapeutics AG expands clinical development team"
steht unter der journalistisch-redaktionellen Verantwortung von
Affimed Therapeutics AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
